Company Encyclopedia
View More
name
Neurocrine Biosciences
NBIX.US
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
1.946 T
NBIX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking15/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.96%A
    • Profit Margin15.95%A
    • Gross Margin66.79%A
  • Growth ScoreB
    • Revenue YoY19.61%B
    • Net Profit YoY10.91%C
    • Total Assets YoY20.67%A
    • Net Assets YoY10.47%B
  • Cash ScoreB
    • Cash Flow Margin626.80%C
    • OCF YoY19.61%B
  • Operating ScoreB
    • Turnover0.69B
  • Debt ScoreB
    • Gearing Ratio29.59%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing

    Neurocrine Biosciences Insider Sold Shares Worth $2,289,083, According to a Recent SEC Filing

    marketscreener·
    US
    NBIX
    +1.49%
    marketscreener·
    US
    NBIX
    +1.49%

    Dir Lyons Sells 15,000 ($2.3M) Of Neurocrine Biosciences Inc [NBIX]

    Gary A. Lyons, Director of Neurocrine Biosciences Inc, sold 15,000 shares worth $2.3M on December 3, 2025, under a prearranged trading plan. The shares were exercised at $47.89 and sold at $152.61. Lyons' ending holdings are 120,482 shares. The transaction was disclosed in a Form 4 filed with the SEC.

    Reuters·
    US
    NBIX
    +1.49%
    Reuters·
    US
    NBIX
    +1.49%

    Director Gary A. Lyons Reports Disposal of Neurocrine Biosciences Inc. Common Shares

    Gary A. Lyons, Director at Neurocrine Biosciences Inc., has reported the disposal of common shares of the company. The original filing is available via EDGAR, the SEC's system. This information is for informational purposes only and not financial advice.

    Reuters·
    US
    NBIX
    +1.49%
    Reuters·
    US
    NBIX
    +1.49%

    Dir Lyons Files To Sell 15,000 Of Neurocrine Biosciences Inc [NBIX]

    Gary A. Lyons, Director of Neurocrine Biosciences Inc, filed a Form 144 with the SEC to sell 15,000 shares of restricted securities on December 3, 2025, through Morgan Stanley Smith Barney LLC, under a prearranged trading plan (10b5-1). This filing allows the sale within 90 days.

    Reuters·
    US
    NBIX
    +1.49%
    Reuters·
    US
    NBIX
    +1.49%

    Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hsbc Holdings PLC

    HSBC Holdings PLC reduced its stake in Neurocrine Biosciences, Inc. by 22.1% in Q2, selling 53,798 shares, now holding 189,237 shares valued at $23.79 million. Neurocrine's Q3 earnings beat estimates with $2.17 EPS and $794.90 million revenue. Analysts rate the stock as a "Moderate Buy" with a $170.53 average price target. Director George J. Morrow sold 15,000 shares, reducing his ownership by 67.97%.

    Market Beat·
    HK
    00005
    -0.45%
    US
    HSBC
    -0.42%
    US
    NBIX
    +1.49%
    Market Beat·
    HK
    00005
    -0.45%
    US
    HSBC
    -0.42%
    US
    NBIX
    +1.49%
    © 2025 Longbridge｜Disclaimer